Tech News

Microsoft-backed universal blood test could start diagnosing disease ‘within a small number of years’

REDMOND — A groundbreaking system that may use synthetic intelligence to diagnose a number of illnesses from a single blood test might not be far off.

The mission, a collaboration between Microsoft and Seattle-based Adaptive Biotechnologies, could start diagnosing situations “inside a small number of years,” stated Peter Lee, company vp of Microsoft Healthcare, talking at a convention for healthcare builders at Microsoft headquarters right here Tuesday.

Lee’s optimism has come alongside method since he first heard the concept.

“This sounds a lot like science fiction. And actually, when the concept was first offered to me by the folks at Adaptive Biotechnologies, I used to be additionally considerably skeptical about this, even supposing that I’m a large fan of Star Trek,” he stated in a reference to the Tricorder, a handheld diagnostic gadget made well-known by the Star Trek franchise.

Lee grew to become satisfied of the concept after seeing how Adaptive was capable of label 100 billion information factors monthly. “The prediction is that, inside a small number of years, we would have sufficient coaching information, if fed to a suitably strong cloud-scale machine studying algorithm, to truly obtain some diagnostic outcomes,” Lee stated.

The system works by decoding details about the immune system that may be learn from a small vial of blood. Adaptive’s know-how decodes the genetic data that’s related to T cells, that are important to immune response. Inside these cells exists “all of the knowledge that’s wanted to find out precisely what most cancers, what infectious illnesses and what autoimmune problems your physique is likely to be dealing with,” Lee stated.

The partnership between Microsoft and Adaptive was first unveiled greater than a yr in the past. In January, the businesses introduced that the AI system is up and running and can initially give attention to diagnosing kind 1 diabetes, celiac disease, ovarian most cancers, pancreatic most cancers and Lyme disease.

As half of the deal, Microsoft invested $45 million in Adaptive, and Adaptive dedicated to spending a minimal of $12 million on Azure cloud companies over seven years.

However with a view to diagnose a disease precisely, the businesses must do greater than learn the immune system. They’ll should know learn how to interpret it. “The issue is, we don’t precisely know learn how to extract this data,” Lee stated.

Adaptive recently filed for an IPO and in doing so, warned that the work with Microsoft won’t go so easily.

“Our collaboration with Microsoft is within the early phases, and our computations and algorithmic-based strategies are largely untested,” the corporate stated, itemizing the cautionary danger elements in its submitting for the general public providing. Adaptive added that the work “might not yield clinically actionable insights on a timetable that’s commercially viable, or in any respect.”

But when the groups are capable of spot disease data from these immune system readings, it’d paved the way to a “utterly universal disease diagnostic, a easy blood test that you simply could take a few times a yr, that may offer you an early prognosis of infectious disease, most cancers and autoimmune problems,” Lee stated. The objective is to do that all inside a few hours at a affordable value.

Microsoft’s cloud enterprise stands to revenue from a world wherein diagnostics shift from laboratories to information facilities, given the huge quantity of computing energy concerned. “These precision medication concepts, these genomics, immunomics and proteomics-based concepts contain gigantic information workloads, information volumes and information complexities that actually defy human comprehension,” Lee stated.

Back to top button

Adblock Detected

Please stop the adblocker for your browser to view this page.